U.S. MARKETS FOR CARDIAC AND VASCULAR TISSUE ENGINEERING PRODUCTS

174 Pages | 26 Exhibits | 2010 Analysis | Forecasts Through 2014 Product Family: Market Reports




OVERVIEW:
Due to the large number of potential patients targeted by tissue engineering and cell transplantation technologies/products under development for cardiac and vascular indications, as well as the major healthcare costs associated with existing treatments for these patients, the potential dollar volume for these technologies/products is substantial, with many applications representing multibillion-dollar opportunities. In the United States (U.S.), the total potential market for tissue engineering and cell transplantation technologies for cardiac and vascular indications is expected to exceed $22.8 billion in the year 2019. Although the current developing market is at a fraction of its potential, advances in the understanding of genetics and cell therapy are expected to drive this market over the forecast period covered by this report.

This upcoming report from Medtech Insight includes analyses of products, markets, competitors, and opportunities in the emerging U.S. market for cardiac and vascular tissue engineering technologies/products. This market, as defined by the scope of this report, includes technologies for myocardial tissue regeneration, restenosis prevention, and therapeutic angiogenesis, as well as tissue-engineered heart valves and vascular grafts.

This report, the first in a series of Medtech Insight reports covering the U.S. tissue engineering and cell transplantation markets, features incidence and procedure volumes figures for the most prevalent coronary and peripheral vascular diseases/disorders, as well as a summary of current research in biomaterials, cell transplantation, gene therapy, stem cells, and tissue regeneration. Upcoming reports in this series will provide analyses of tissue engineering and cell transplantation product markets for musculoskeletal, neurologic, urologic, organ regeneration, and skin replacement applications.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

i. Cardiovascular Disease Overview
	a. Coronary Artery Disease
	b. Cardiomyopathy
	c. Heart Failure
	d. Heart Valve Dysfunction
	e. Heart Transplantation
	f. Peripheral Artery Disease
	g. Abdominal Aortic Aneurysm
ii. Tissue Engineering Technologies
	a. Biomaterials
	b. Cell Culture Technology
	c. Stem Cell Technology
	d. Immunoisolation Technology
iii. Tissue Engineering and Cell Transplantation: Cardiac and Vascular Products Market
	a. Tissue-Engineered Heart Valves
	b. Tissue-Engineered Vascular Grafts
	c. Myocardial Tissue Regeneration
	d. Therapeutic Angiogenesis
	e. Restenosis Prevention
	f. Market Analysis
iv. Methodology

Exhibit ES-1: Heart Failure, Selected Statistics
Exhibit ES-2: Tissue-Engineered Cardiac and Vascular Products, Potential Market Forecast, 2009 and 2019

1. CARDIOVASCULAR DISEASE OVERVIEW

1.1 The Heart and Circulatory System
1.2 Selected Cardiovascular Diseases/Disorders
	1.2.1 Coronary Artery Disease
		1.2.1.1 Atherosclerosis
		1.2.1.2 Myocardial Infarction
		1.2.1.3 Coronary Artery Bypass Graft Surgery
	1.2.2 Cardiomyopathy
		1.2.2.1 Dilated Cardiomyopathy
		1.2.2.2 Hypertrophic Cardiomyopathy
		1.2.2.3 Restrictive Cardiomyopathy
	1.2.3 Heart Failure
		1.2.3.1 Disease Development
		1.2.3.2 Ejection Fraction Reduction
		1.2.3.3 Classification/Staging Systems
	1.2.4 Heart Valve Dysfunction
	1.2.5 Heart Transplantation
		1.2.5.1 Alternative to Transplantation
	1.2.6 Peripheral Artery Disease
		1.2.6.1 Abdominal Aortic Aneurysm

Exhibit 1-1: United States Population, by Age Group, Selected Years, 2000-2050
Exhibit 1-2: Cross-Section Diagram of the Heart
Exhibit 1-3: Statistics for Selected Coronary Artery Disease Risk Factors
Exhibit 1-4: Myocardial Infarction, Selected Statistics
Exhibit 1-5: Coronary Artery Bypass Graft Surgery, Procedure Volumes Forecast, 2009-2014
Exhibit 1-6: Cardiomyopathy, Selected Statistics
Exhibit 1-7: Heart Failure, Selected Statistics
Exhibit 1-8: Summary, New York Heart Association Heart Failure Classification System
Exhibit 1-9: Summary, American College of Cardiology/American Heart Association Heart Failure Staging System
Exhibit 1-10: Heart Valve Replacement and Repair, Procedure Volumes Forecast, 2009-2014
Exhibit 1-11: Heart Transplantation, Historical Procedure Volumes, 1998-2008
Exhibit 1-12: Femoropopliteal Bypass, Procedure Volumes Forecast, 2009-2014
Exhibit 1-13: Abdominal Aortic Aneurysm Repair, Procedure Volumes Forecast, 2009-2014

2. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES

2.1 Biomaterials
	2.1.1 Synthetic Biomaterials
	2.1.2 Biologically Derived Biomaterials
		2.1.2.1 Collagen
		2.1.2.2 Xenogeneic Tissue
	2.1.3 Hybrid Biomaterials
	2.1.4 Genetically Engineered Biomaterials
		2.1.4.1 Deoxyribonucleic Acid Transfection Vectors
		2.1.4.2 Genetically Manipulated Cells
		2.1.4.3 Three-Dimensional Polymer Technology
		2.1.4.4 Transgenics
		2.1.4.5 Fibroblasts
		2.1.4.6 Immortalized Neural Stem Cells
		2.1.4.7 Gene-Activated Matrices
	2.1.5 Scaffolds
	2.1.6 Vascular Grafts
2.2 Cell Culture Technology
	2.2.1 Bioreactors
		2.2.1.1 Flatbed Perfusion Systems
		2.2.1.2 Hollow Fiber Bioreactor Systems
		2.2.1.3 Cell Suspension Systems
		2.2.1.4 Disposable Bioreactors
2.3 Stem Cell Technology
	2.3.1 Cell Extraction and Expansion
	2.3.2 Bioreactors
2.4 Immunoisolation Technology
	2.4.1 Chimeric Immunity
	2.4.2 Cell Encapsulation Technology

Exhibit 2-1: 2010, Selected Synthetic Biomaterials Used in Tissue Engineering
Exhibit 2-2: 2010, Selected Natural Biomaterials Used in Tissue Engineering
Exhibit 2-3: 2010, Selected Current and Emerging Cell Extraction, Expansion, and Separation Products and Technologies

3. TISSUE ENGINEERING AND CELL TRANSPLANTATION: CARDIAC AND VASCULAR PRODUCTS MARKET

3.1 Emerging Technologies
	3.1.1 Tissue-Engineered Heart Valves
		3.1.1.1 Products and Emerging Technologies
			3.1.1.1.1 AutoTissue
			3.1.1.1.2 CryoLife
		3.1.1.2 Selected Research
	3.1.2 Tissue-Engineered Vascular Grafts
		3.1.2.1 Products and Emerging Technologies
			3.1.2.1.1 Bio Nova International
			3.1.2.1.2 Cytograft Tissue Engineering
			3.1.2.1.3 LeMaitre Vascular
			3.1.2.1.4 Tissue Genesis
			3.1.2.1.5 VasoTissue Technologies
		3.1.2.2 Selected Academic and Government Research
			3.1.2.2.1 Collagen/Fibrin Matrix
			3.1.2.2.2 Electrospinning
			3.1.2.2.3 Genetically Altered Tissue
			3.1.2.2.4 Stem Cells
			3.1.2.2.5 Synthetic Scaffolds
	3.1.3 Myocardial Tissue Regeneration
		3.1.3.1 Products and Emerging Technologies
			3.1.3.1.1 Aastrom Biosciences
			3.1.3.1.2 Advanced Cell Technology
			3.1.3.1.3 Amorcyte
			3.1.3.1.4 Angioblast Systems
			3.1.3.1.5 Bioheart
			3.1.3.1.6 Cardio3 BioSciences
			3.1.3.1.7 Cardium Therapeutics
			3.1.3.1.8 Celladon
			3.1.3.1.9 Cook Biotech/Cook Group and CorMatrix Cardiovascular
			3.1.3.1.10 Cytori Therapeutics
			3.1.3.1.11 Geron
			3.1.3.1.12 miRagen Therapeutics
			3.1.3.1.13 NellOne Therapeutics
			3.1.3.1.14 Osiris Therapeutics
			3.1.3.1.15 TCA Cellular Therapy
		3.1.3.2 Selected Academic Research
	3.1.4 Therapeutic Angiogenesis
		3.1.4.1 Routes of Administration
		3.1.4.2 Protein Therapy
		3.1.4.3 Transmyocardial Revascularization
		3.1.4.4 Products and Emerging Technologies
			3.1.4.4.1 Aastrom Biosciences
			3.1.4.4.2 Aldagen
			3.1.4.4.3 AnGes MG
			3.1.4.4.4 Arteriocyte
			3.1.4.4.5 Athersys
			3.1.4.4.6 Baxter International
			3.1.4.4.7 CardioVascular BioTherapeutics
			3.1.4.4.8 Cardium Therapeutics
			3.1.4.4.9 Harvest Technologies
			3.1.4.4.10 Medistem
			3.1.4.4.11 sanofi-aventis
			3.1.4.4.12 TCA Cellular Therapy
	3.1.5 Restenosis Prevention
		3.1.5.1 Products and Emerging Technologies
			3.1.5.1.1 Angioblast Systems
			3.1.5.1.2 Genzyme
			3.1.5.1.3 Global Therapeutics/Cook Medical/Cook Group
			3.1.5.1.4 OrbusNeich
			3.1.5.1.5 Pervasis Therapeutics
			3.1.5.1.6 Tepha
			3.1.5.1.7 VesselTek BioMedical
3.2 Market Analysis
	3.2.1 Market Drivers
		3.2.1.1 Angiogenesis
		3.2.1.2 Congenital Heart Defect Repair Products
		3.2.1.3 Heart Valves
		3.2.1.4 Myocardial Tissue Regeneration
		3.2.1.5 Restenosis Prevention
		3.2.1.6 Vascular Grafts
	3.2.2 Market Limiters
3.3 Competitive Analysis

Exhibit 3-1: Technologies in Tissue Engineering and Cell Transplantation for Cardiac and Vascular Applications, by Indication, 2009 and 2019
Exhibit 3-2: 2010, Selected Tissue-Engineered Heart Valves
Exhibit 3-3: 2010, Selected Emerging Tissue-Engineered Vascular Grafts
Exhibit 3-4: 2010, Selected Emerging Tissue-Engineered Myocardial Regeneration Products
Exhibit 3-5: 2010, Selected Emerging Tissue-Engineered Angiogenesis Products
Exhibit 3-6: 2010, Selected Emerging Tissue-Engineered Restenosis Prevention Products
Exhibit 3-7: Tissue-Engineered Cardiac and Vascular Products, Potential Market Forecast, 2009 and 2019
Exhibit 3-8: Tissue-Engineered Cardiac and Vascular Products, Product Introduction Forecast, by Indication, 2014 and 2019

4. COMPANY PROFILES

4.1 AnGes MG, Inc.
4.2 Athersys, Inc.
4.3 Baxter International, Inc.
4.4 Bioheart, Inc.
4.5 Cardio3 BioSciences SA
4.6 CardioVascular BioTherapeutics, Inc.
4.7 CryoLife, Inc.
4.8 Cytograft Tissue Engineering, Inc.
4.9 Harvest Technologies Corporation
4.10 OrbusNeich Co. Ltd
4.11 Sanofi-aventis SA

APPENDIX:  COMPANY LISTING


COMPANIES COVERED:

  1. AnGes MG, Inc.
  2. Athersys, Inc.
  3. Baxter International, Inc.
  4. Bioheart, Inc.
  5. Cardio3 BioSciences SA
  6. CardioVascular BioTherapeutics, Inc.
  7. CryoLife, Inc.
  8. Cytograft Tissue Engineering, Inc.
  9. Harvest Technologies Corporation
  10. OrbusNeich Co. Ltd
  11. sanofi-aventis SA
Contact Us

Need help finding medtech research? Let us help you!